Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Andera Partners

CIK 0001757283
$206.5M
Reported AUM
8
Positions
Q2 2026
Period
2026-07-22
Filed

Editorial summary

Summary for Andera Partners · Q2 2026 is not yet generated. It will appear here after the next nightly run.

Portfolio · Q2 2026

KMTS$69.4MMLYS$42.9MAVLN$30.6MAGMB$20.0MEVMN$18.5MIVA$13.7MABVX$10.4MAP

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1KMTSKESTRA MED TECHNOLOGIES LTD$23.151.76%50.52%-3.78%$69.4M33.62%HELD
2MLYSMINERALYS THERAPEUTICS INC$26.19-0.61%90.49%66.22%$42.9M20.80%HELD
3AVLNAVALYN PHARMACEUTICALS INC$29.314.31%-3.49%0.07%$30.6M14.82%HELD
4AGMBAGOMAB THERAPEUTICS NV$12.762.90%-12.94%21.59%$20.0M9.67%HELD
5EVMNEVOMMUNE INC$11.352.71%-39.65%-35.11%$18.5M8.96%HELD
6IVAINVENTIVA SA$4.622.44%42.55%-65.23%$13.7M6.65%HELD
7ABVXABIVAX SA$124.334.62%72.81%1124.93%$10.4M5.04%HELD
8NYXHNYXOAH S A$1.411.44%-80.55%-95.70%$882K0.43%HELD

Source: SEC EDGAR · accession 0001757283-26-000015. 13F discloses long positions only — shorts, foreign equities, and options are excluded.